Jingui Mu

Title: Innovations of Jingui Mu in Anticoagulation Therapy

Introduction

Jingui Mu is an accomplished inventor based in Shanghai, CN, with a notable contribution to the field of anticoagulation therapy. He holds two patents that showcase his innovative approach to improving medical treatments through genetic modifications.

Latest Patents

Mu's latest patents include the development of genetically modified tissue factor pathway inhibitor (TFPI) sequences aimed at enhancing anticoagulation efficacy. These patents detail a novel sequence known as long half-life genetically modified TFPI (LTFPI), where specific amino acids, such as lysine and asparagine, have been strategically mutated to optimize the protein's functionality. The invention highlights a method of producing LTFPI through high-efficiency expression from a yeast production system, thereby provided a valuable tool for treating coagulation issues.

Career Highlights

Jingui Mu is affiliated with Fudan University, where his research focuses on exploring innovative methods to address coagulation challenges in medicine. His expertise in genetic engineering has led him to make significant strides in developing biopharmaceutical products. Through his patents, he aims to facilitate improved treatment options for patients suffering from coagulation disorders.

Collaborations

Mu has collaborated with esteemed colleagues, including Duan Ma and Jiping Wang. Together, they work on cutting-edge research that merges genetics and pharmacology, driving forward innovations in medical science. Their combined efforts have helped to create new avenues for treatment and advance the field of anticoagulation therapy.

Conclusion

Jingui Mu stands out as a prominent inventor in the biomedical field, with his patents revolutionizing anticoagulant therapies. His work at Fudan University, along with his collaborations, underscores the importance of innovation in medicine, ultimately benefiting patients worldwide through advancements in treatment methodologies.